ReviewPediatric blood & cancer2013
Children's Oncology Group's 2013 blueprint for research: rare tumors.
Review in Pediatric blood & cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- A review of Leila Rose Foundation support for families affected by rare childhood cancer in Australia over the past decade.Cancer reports (Hoboken, N.J.) · 2022Pooled it
- A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT).Pediatric surgery international · 2013Trial
- KIF14 in cancer biology: implications for diagnosis and therapy.Clinical & experimental metastasis · 2026Review
- Utility of bone marrow examination in retinoblastoma and their correlation with hematological features.Journal of medicine and life · 2023Article
- Pitfalls in the diagnosis of yolk sac tumor: Lessons from a clinical trial.Pediatric blood & cancer · 2022Article
- Juvenile Granulosa Cell Tumor as the Presenting Feature of McCune-Albright Syndrome.Journal of the Endocrine Society · 2021Article
- Article
- Hepatic nodules with arterial phase hyperenhancement and washout on enhanced computed tomography/magnetic resonance imaging: how to avoid pitfalls.Abdominal radiology (New York) · 2020Review
- Fine Particulate Matter Air Pollution and Mortality among Pediatric, Adolescent, and Young Adult Cancer Patients.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Hepatoblastoma: Transplant Versus Resection Experience in a Latin American Transplant Center.Transplantation direct · 2017Article
- A change roadmap towards research paradigm in low-resource countries: retinoblastoma model in Egypt.International ophthalmology · 2017Article
- Developing therapies for rare tumors: opportunities, challenges and progress.Expert opinion on orphan drugs · 2016Article
- Rare childhood cancers--an increasing entity requiring the need for global consensus and collaboration.Cancer medicine · 2015Article
- The Children's Oncology Group: Organizational Structure, Membership, and Institutional Characteristics.Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology NursesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 1 country.
Funding
Abstract
In the US, approximately 2,000 children are diagnosed with rare cancers each year, with 5-year survival ranging from <20% for children with advanced carcinomas to >95% for children with intraocular retinoblastoma or localized germ cell tumors. During the last years, 12 clinical studies have been successfully completed in children with retinoblastoma, liver tumors, germ cell tumors, and infrequent malignancies, including therapeutic, epidemiologic, and biologic studies. Current efforts are centered in the development of large international collaborations to consolidate evidence-based definitions and risk stratifications that will support international Phase 3 clinical trials in germ cell tumors, hepatoblastoma, and other rare cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.